
DexCom, Inc.
DXCMNASDAQHealthcareMedical - Devices
最新資料
US$92.33
+US$2.12 · +2.35%
DXCM公司概覽
盤中時間採用ET。市場資料可能有所延遲。
GoAI 研究快照
簡明呈現最新可用的模型資訊。
GoAI評分
Buy
Favorable setup — positive multi-factor alignment
估值
88
Deep Value
動能
56
Neutral
情緒
66
Bullish
風險韌性
60
Moderate Risk
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
人工智慧產生的上下文僅供參考,並非投資建議。
公司概況
公司網站DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
- 產業
- Medical - Devices
- 部門
- Healthcare
- 總部
- US
- 執行長
- Jacob Steven Leach
- 上市以來
- 2005年4月14日
- 僱員
- 11,050
市場位置
- 成交量
- 348.18萬
- 0.62× 平均值
- 平均成交量
- 560.22萬
- 日均成交量
- 市值
- 348.46億 USD
- 貝塔
- 1.41
- 市場參考 1
財務數據
財務快照
最近十二個月估值與收益率
- 本益比(TTM)
- 35.65×
- 股價淨值比(TTM)
- 13.52×
- 股價營收比(TTM)
- 7.01×
- 股息率
- 0.00%
獲利能力和效率
- 毛利率
- 62.47%
- 營業利益率
- 22.92%
- 淨利潤率
- 20.12%
財務健康
- 負債權益比
- 0.53×
DXCM同業公司
繼續GoAI的研究
在 GoAI 中研究DXCMresearch.disclaimer





